EMA Approval And Global Launch Will Expand Oncology Markets

Published
09 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
€104.60
21.2% undervalued intrinsic discount
14 Aug
€82.45
Loading
1Y
108.1%
7D
-0.3%

Author's Valuation

€104.6

21.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 23%

Shared on23 Apr 25
Fair value Decreased 15%

AnalystConsensusTarget has decreased revenue growth from 36.0% to 30.4% and increased future PE multiple from 7.6x to 9.1x.

Shared on17 Apr 25
Fair value Increased 18%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 6.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Decreased 20%

AnalystConsensusTarget has decreased revenue growth from 43.9% to 36.0%.